Following the science to improve patient outcomes
What will make the biggest difference?
Recent developments in the understanding of respiratory disease pathways mean that we are entering an era of unprecedented potential to deliver scientific breakthroughs and transform the lives of people with asthma and COPD. Our 40-year heritage in respiratory science is just the beginning of our story. Hear more from the people at AstraZeneca behind our commitment to respiratory disease.
Whether you’re a bench scientist, whether you’re in commercial, whether you’re in development, it’s taking great ideas, innovative science and translating them into medicines that are going to make a transformational difference to patients. That’s what drives us, and that’s what science can do.
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.
Respiratory (as at 18 May 2018)
I have a passion to develop medicines that help patients who don’t otherwise have options. This is very rewarding and motivating for me, and keeps me focused on seeking the evidence, and collaborating with other investigators who share a similar vision to pursue the science that benefits all of mankind.Roland Kolbeck, PhD, VP, R&D Respiratory, Inflammation and Autoimmunity (RIA)
Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations.
You should visit your local AstraZeneca site to find out more about our medicines in your country. In some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.
New England Journal of Medicine publishes two trials for Symbicort as an anti-inflammatory reliever therapy ‘as needed’ in mild asthma
AstraZeneca is advancing clinical practice in respiratory medicine with new data at the American Thoracic Society 2018 International Congress
Our focus on unmet medical needs
Improving patient outcomes with tailored therapies, devices, and support tools
Global burden of respiratory diseases
Raising awareness of the ongoing unmet medical need in asthma, COPD and idiopathic pulmonary fibrosis (IPF)
Inhaled therapies and novel combinations
Optimising our portfolio of inhaled medicines to improve choice and outcomes for patients across the disease spectrum
Targeted biologic therapies
Using new scientific insights about the biology of respiratory diseases and patient phenotypes to create targeted biologic therapies
AstraZeneca’s work environment is dynamic and fosters innovation. We believe where there’s energy, there’s fulfillment, and with jobs from Cambridge, UK to Shanghai, China, we’ve got the role for you.
Veeva ID: Z4-10685 Date of next review: May 2020